Tag: quarterly report

GARDENA, California, June 02, 2026 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup and solar hybrid DC power solutions, today highlighted its financial results for its first quarter ended March 31, 2026, which the Company disclosed by its quarterly report on Form 10-Q with the Securities and Exchange Commission on May 20, 2026, and its recent operational progress. The quarter reflected substantial year-over-year gains in gross margin, operating results, and balance sheet strength, supported by a $3.7 million sales order backlog as of March 31, 2026.

WINTER PARK, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”), an owner and operator of high-quality open-air retail centers located primarily in high-growth markets across the Southeast and Southwest, announced today the sale of Madison Yards, a 163,000-square-foot grocery-anchored shopping center in Atlanta, Georgia (the “Property”) for $73.3 million, representing a price of $451 per square foot.

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Shares of Nutex Health Inc. (NASDAQ: NUTX) experienced a precipitous decline today, falling as much as 24% in intraday trading. The significant drop followed the company’s disclosure that it would not timely submit its financial results for the quarter ended June 30, 2025 - a development related to an ongoing investigation by law firm Hagens Berman into possible securities violations.

CINCINNATI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the second quarter ended June 30, 2025.

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES" or the "Company"), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended June 30, 2025, with the U.S. Securities and Exchange Commission (“SEC”).

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH